Effects of Duloxetine on Painful Physical Symptoms Associated With Depression

Harvard University, Cambridge, Massachusetts, United States
Psychosomatics (Impact Factor: 1.86). 03/2004; 45(1):17-28. DOI: 10.1176/appi.psy.45.1.17
Source: PubMed


Painful physical symptoms are common features of major depressive disorder and may be the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) and norepinephrine reuptake inhibitor duloxetine on emotional and painful physical symptoms in outpatients with major depressive disorder was evaluated in three randomized, double-blind, placebo-controlled trials. The trials' primary objective was to evaluate the effect of duloxetine on mood, and subjects were not enrolled on the basis of presence, type, or severity of pain. However, the pain-relieving effects of duloxetine were evaluated by a priori defined analyses of results from a visual analogue scale and the Somatic Symptom Inventory. Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression.

11 Reads
  • Source
    • "Furthermore, patients included in this study are screened for pain symptoms, differentiating between nociceptive and neuropathic pain, unlike the studies of Goldstein et al. [107]. Therefore, pain relief can be thoroughly evaluated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The comorbidity of pain and depression is associated with high disease burden for patients in terms of disability, wellbeing, and use of medical care. Patients with major and minor depression often present themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving. Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness of an integrated approach of pain in depressed patients has not been studied. This article describes the aims and design of a study to evaluate effects and costs of collaborative care with the antidepressant duloxetine for patients with pain symptoms and a depressive disorder, compared to collaborative care with placebo and compared to duloxetine alone. This study is a placebo controlled double blind, three armed randomized multi centre trial. Patients with (sub)chronic pain and a depressive disorder are randomized to either a) collaborative care with duloxetine, b) collaborative care with placebo or c) duloxetine alone. 189 completers are needed to attain sufficient power to show a clinically significant effect of 0.6 SD on the primary outcome measures (PHQ-9 score). Data on depression, anxiety, mental and physical health, medication adherence, medication tolerability, quality of life, patient-doctor relationship, coping, health resource use and productivity will be collected at baseline and after three, six, nine and twelve months. In the collaborative care conditions a) and b), a care-manager provides Problem Solving Treatment and integrated symptom management guidance with a self-help manual, monitors depressive and pain symptoms, and refers patients to a physiotherapist for treatment according to a 'Graded Activity' protocol. A psychiatrist provides duloxetine or placebo and pain medication according to algorithms, and also monitors pain and depressive symptoms. In condition c), the psychiatrist prescribes duloxetine without collaborative care. After 12 weeks, the patient is referred back to the general practitioner with a consultation letter, with information for further treatment of the patient. This study enables us to show the value of a closely monitored integrated treatment model above usual pharmacological treatment. Furthermore, a comparison with a placebo arm enables us to evaluate effectiveness of duloxetine in this population in a real life setting. Also, this study will provide evidence-based treatments and tools for their implementation in practice. This will facilitate generalization and implementation of results of this study. Moreover, patients included in this study are screened for pain symptoms, differentiating between nociceptive and neuropathic pain. Therefore, pain relief can be thoroughly evaluated. Trial registration NTR1089
    BMC Psychiatry 05/2013; 13(1):147. DOI:10.1186/1471-244X-13-147 · 2.21 Impact Factor
  • Source
    • "cance . Mean changes at endpoint in depression rating scales ( HAMD - 17 and CGI - S ) also did not differ significantly between duloxetine ( 60 mg ) and placebo treatment groups . A summary of pooled data from 3 clinical trials , however , found that , compared with placebo , duloxetine was associated with significant reduction in pain severity ( Goldstein et al . , 2004 ) . Perahia et al . ( 2008b ) found that pa - tients who did not respond to initial treatment with an SSRI and were switched to duloxetine ( 60 mg / day ) saw significant im - provement in VAS overall pain scores ."

    Open Journal of Depression 01/2013; 02(04):54-63. DOI:10.4236/ojd.2013.24011
  • Source
    • "Duloxetine has also demonstrated an important indication in patients with mood disorder (MD) associated with painful physical symptoms (Fava et al., 2004; Brecht et al., 2007; Russell et al., 2008), so this drug could be particularly useful in cancer patients in which pain is frequently associated with depression (Goldstein et al., 2004; Wise et al., 2007; Beesdo et al., 2009). DLX has been found to be effective in other pathologies in which pain is frequently associated with depression, such as diabetic peripheral neuropathy (Raskin et al., 2005) and fibromyalgia (Uçeyler et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the efficacy and tolerability of duloxetine in cancer patients with mood disorder (MD) by means of a comparison with a matched control group of patients with MD without medical illness. Fifty-nine consecutive patients with MD were enrolled in this prospective case-control study and received duloxetine 60/120 mg per day for 12 weeks. Twenty-seven patients were affected by cancer, whereas 32 had an MD without cancer. All the patients were assessed by means of efficacy and effectiveness tolerability scales for depression (Montgomery-Asberg Depression Rating Scale and Hospital Anxiety and Depression Scale), anxiety (State-Trait Anxiety Inventory-Y1/Y2) and severity of symptoms (Clinical Global Impression (CGI)-Severity) at baseline (T0), after 4 weeks (T1) and 12 weeks (T2). The CGI-Improvement, CGI-Effectiveness Index and Dosage Record Treatment Emergent Symptom Scale were administered at T1 and T2. A significant global improvement in all the efficacy measures was found. The results showed no significant interaction 'Time X Group', suggesting a similar improvement in efficacy scores for cancer-depressed patients and depressed patients without cancer. No difference was found between the two groups with regard to drop-out percentage, effectiveness and tolerability. Although the results of this case-control study are preliminary, they suggest that duloxetine can be considered a good option for the treatment of MD in cancer patients. Copyright © 2011 John Wiley & Sons, Ltd.
    Human Psychopharmacology Clinical and Experimental 06/2011; 26(4-5):291-9. DOI:10.1002/hup.1202 · 2.19 Impact Factor
Show more